Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma

Trial Profile

Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Adenocarcinoma; Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Primary endpoint (Progression free survival) has been met, according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results assessing safety and efficacy, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Apr 2016 Planned End Date changed from 1 Jan 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top